Benign prostatic hyperplasia Endoscopic enucleation Laser vaporization Photoselective vaporization Prostate artery embolization Prostate cancer Prostate specific antigen REZUM Simple prostatectomy TUMT TUNA TURP Urolift iTIND

Focal therapy IDEAL Prostate cancer

benign prostatic hyperplasia lower urinary tract symptoms nonalcoholic fatty liver disease prostate cancer prostatic diseases

5-alpha Reductase Inhibitors Humans Male Oxidoreductases Prospective Studies *Prostatic Hyperplasia/drug therapy *Prostatic Neoplasms/drug therapy 5?-reductase inhibitors Bph Prostate cancer cancer specific mortality meta-analysis

Cystectomy Humans Male Prostate *Prostatic Hyperplasia/surgery *Transurethral Resection of Prostate Treatment Outcome *Urinary Bladder Neoplasms/surgery Bladder cancer benign prostatic hypertrophy prostate cancer transurethral resection

Benign prostatic hyperplasia Epidemiological. Meta-analysis Prostate cancer Prostatitis

Glutathione Glutathione Peroxidase Humans Male *Prostatic Hyperplasia *Prostatic Neoplasms Sulfhydryl Compounds Antioxidants benign prostatic hyperplasia biomarkers oxidative stress prostate cancer

Biomarkers/analysis Humans Male MicroRNAs/*analysis Prostatic Hyperplasia/*diagnosis/metabolism Benign prostatic hyperplasia Diagnosis Prostate cancer Therapy miRNA

Benign Prostatic Hyperplasia Prostate Cancer Bladder Cancer Meta-Analysis

Adult Aged Aged 80 and over Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use B7-H1 Antigen/antagonists & inhibitors Carcinoma/*drug therapy/immunology/mortality/pathology Clinical Decision-Making Female Humans Immune Checkpoint Inhibitors/adverse effects/*therapeutic use Male Middle Aged Patient Selection Progression-Free Survival Time Factors Urinary Bladder Neoplasms/*drug therapy/immunology/mortality/pathology Urothelium/*drug effects/immunology/pathology Immune-checkpoint inhibitor Meta-analysis Programmed death-ligand 1 Urothelial carcinoma interests/personal relationships which may be considered as potential competing interests: The authors certify that all conflicts of interest including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the article are listed as follows: Shahrokh Shariat owns or co-owns the following patents: methods to determine prognosis after therapy for prostate cancer. Granted 2002-09-06. Methods to determine prognosis after therapy for bladder cancer. Granted 2003-06-19. Prognostic methods for patients with prostatic disease. Granted 2004-08-05. Soluble Fas: urinary marker for the detection of bladder transitional cell carcinoma. Granted 2010-07-20. He has a consulting or advisory role for the following: Astellas Astra Zeneca Bayer BMS Cepheid Ferring Ipsen Jansen Lilly MSD Olympus Pfizer Pierre Fabre Roche Sanochemia Sanofi Takeda Urogen and Wolff. All remaining authors have declared no conflicts of interest.

Animals Biological Availability Clinical Trials as Topic Flavonoids/pharmacology/*therapeutic use Flavonols/pharmacology/*therapeutic use Humans Inhibitory Concentration 50 Kaempferols/pharmacology/*therapeutic use Male Models Animal Prostatic Neoplasms/*drug therapy Urinary Bladder Neoplasms/*drug therapy bladder cancer fisetin kaempferol myricetin prostate cancer

Androgen Antagonists/*therapeutic use Humans Male Observational Studies as Topic Prostatic Neoplasms/*drug therapy Risk Assessment Urinary Bladder Neoplasms/epidemiology/*prevention & control Androgen deprivation therapy Bladder cancer Pharmacoepidemiology Prostate cancer Systematic review

Coloring Agents Humans Indocyanine Green Lymph Node Excision *Lymphatic Metastasis/diagnostic imaging *Lymphography Male Pelvis *Prostatic Neoplasms/diagnostic imaging/pathology Sentinel Lymph Node Biopsy *Urinary Bladder Neoplasms/diagnostic imaging/pathology Cáncer de Próstata Ganglio centinela Linfadenectomía Lymph node dissection Prostate cáncer Sentinel lymph node Verde de Indocianina

prostate cancer radiation radical prostatectomy radiotherapy secondary bladder cancer

Contrast Media Diagnosis Differential Female Humans Lymphatic Metastasis/*diagnostic imaging/pathology Magnetic Resonance Imaging/*methods Male Prostatic Neoplasms/*pathology Sensitivity and Specificity Urinary Bladder Neoplasms/*pathology Mri bladder cancer lymph node metastasis meta-analysis prostate cancer